How to prepare an IND annual report

What should an IND annual report contain?

Under §312.33, reconcile the reporting period with the IND effective-date anniversary and summarize individual study progress, safety and other relevant scientific developments. Include significant manufacturing changes, required brochure and protocol updates, the coming-year investigational plan and foreign marketing developments. Trace each count and conclusion to its source; a copied study list is not a complete annual progress report.

Before you begin

IND annual reports under current 21 CFR 312.33; not an NDA/ANDA annual report or automatic replacement by a global DSUR.

What you will prepare: A reconciled IND progress report with traceable summaries, study records and forward plan.

1.13.8: establish the interval and study register

Retrieve the IND effective date, preceding report, actual reporting interval and current study register. Under 312.33, the report is due within 60 days of the effective-date anniversary. Reconcile the interval before requesting data; a one-month gap between departmental extracts can omit relevant events.

For each ongoing study and each study completed in the preceding year, prepare title/protocol identifier, purpose, population and status. Reconcile planned enrollment, enrollment to date with the specified demographic tabulations, completions and withdrawals. Add available results for completed studies or known interim results, with the relevant cutoff and limitations. A status of “ongoing” should not conceal stopped recruitment or treatment.

An editorial study table can hold: protocol/version; purpose/population; status at cutoff; planned/enrolled/completed/withdrawn counts; available results; source and owner. Have clinical operations and data management explain discrepancies before the narrative is finalized.

1.13.1–1.13.3: write interval findings, not recycled summaries

1.13.1: Nonclinical studies: identify studies completed or in progress during the year, their status and major findings. Reconcile the list with nonclinical records, including studies with unfavorable findings. Explain what changed in the understanding of the program and point to full reports already submitted or supplied in their proper location.

1.13.2: Clinical pharmacology: summarize interval information relevant to the drug's actions, such as dose response or bioavailability, with the population, exposure and evidence limitations. Avoid simply pasting the initial rationale from the IND.

1.13.3: Safety: assemble the most frequent and most serious adverse experiences by body system, the summary of IND safety reports, subjects who died with causes, and withdrawals associated with adverse experiences regardless of suspected relationship. Reconcile denominators, cutoffs and event terms with the safety owner. A periodic summary does not replace a separately due IND safety report or establish that every event is drug-related.

1.13.5–1.13.7: explain meaningful changes and their disposition

1.13.5: Manufacturing: collect the interval change-control register, affected product/process/batches, dates and relevant submission references. Summarize significant manufacturing changes and their implications for investigational material. Do not label a change insignificant solely because it was already submitted.

1.13.6: Microbiology: identify significant changes in microbiological controls, processes or relevant findings, and explain the link to product quality. Keep the scientific interpretation with the responsible quality/microbiology reviewer; use the same batch and site identities as the CMC records.

1.13.7: Other significant new information: account for relevant material that does not fit the preceding summaries, with a clear explanation of its relevance and actual submission location. If the investigator brochure changed, describe the revision and provide the new brochure as required by 312.33(d). Include significant Phase 1 protocol modifications not previously reported in an amendment. Do not use the family as a reason to omit those required topics or as permission to postpone a separate amendment.

1.13.9, 1.13.10 and 1.13.14: connect the past year to the next

1.13.9: General investigational plan: replace the preceding year's plan with the coming-year program. Describe the rationale, indications, general approach, planned studies, estimated patient numbers and anticipated serious risks in the applicable 312.23(a)(3)(iv) framework. If plans do not yet cover the whole year, say so. Show how interval findings changed the plan. A copied timeline with expired milestones is not a forward-looking plan.

1.13.10: Foreign marketing: report significant developments such as foreign approvals, withdrawals or suspensions, identifying product/use, country, date and significance to development. This is different from distribution quantities under a marketed-product annual report.

1.13.14: Outstanding regulatory business: the IND regulation makes this log optional. When useful, list the actual unanswered item, submission/date/reference, requested response and owner. Remove closed items based on the response record, not an assumption. An optional heading must not be labeled universally mandatory.

Worked review: the same study has three incompatible cutoffs

Fictional editorial exercise: clinical operations reports 120 enrolled participants at the annual cutoff, safety lists 128 exposed participants a month later, and the draft calls both figures the reporting-period total. Reconcile the populations and dates; do not force the numbers to match by deletion. Clearly distinguish cumulative from interval counts and enrolled from exposed populations.

If the safety extract is missing, the safety section is incomplete rather than “no new information.” If the IND has changed status, have the regulatory owner confirm the continuing reporting obligation before copying the preceding year's package.

Reconcile study counts before drafting the safety narrative

Use a working record that states what each number counts. Counts can legitimately differ because they measure different populations or periods; the task is to explain those differences, not force every table to display the same total.

Reconciliation exercise: the study register has 120 enrolled participants. The safety extract includes 116 treated participants. Four participants enrolled but never received treatment. If both records use the same cutoff and those definitions are confirmed, the difference can be explained without changing either number. If the safety extract instead uses a later cutoff, retrieve aligned data or explain and resolve the mismatch before describing both as the annual-period total. Do not infer the reason for a discrepancy from arithmetic alone.

The adverse-experience withdrawal list is not limited to events the investigator considered drug-related. Preserve the required cases and describe causality accurately. Likewise, a death belongs in the required account with its cause; its inclusion does not assert that the drug caused it. Use the safety reviewer to reconcile event terminology and interpretation.

Connect the retrospective findings to the coming-year plan. For example, if a newly identified uncertainty changes the planned dose-ranging work, show the change in the study plan and its rationale. Avoid promising a study as decided when it is still contingent on evidence or FDA interaction. Section 312.33(c) calls for replacing the preceding general investigational plan, not merely appending another expired timeline.

At the document handoff, check the revised brochure against the narrative and supplied copy, and compare significant Phase 1 protocol modifications with earlier amendments. Use the information-amendment guide for the separate transaction assessment. If the annual package is a DSUR, perform the same U.S. content reconciliation rather than assuming its title proves coverage.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides